Sanofi
Sanofi is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines. Its portfolio spans specialty medicines, immunology, rare diseases, neurology, and vaccines, with operations and sales across major global markets through a mix of direct and partnered channels.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenuePrescription medicines sold across specialty, chronic, and specialty-care therapeutic areas.
Preventive vaccines distributed to healthcare systems, clinics, and public programs.
Longer-established originator medicines and mature products sold globally.
R&D-driven development activity supporting future product launches and lifecycle expansion.
Customers
Sanofi sells mainly to healthcare systems, pharmacies, hospitals, physicians, and public immunization programs that purchase medicines and vaccines for patient treatment and prevention. It also serves payers and government buyers that influence formulary access, pricing, and reimbursement across markets. Demand depends on clinical adoption, regulatory approval, and broad access through national health systems and private channels.
Buy specialty medicines and hospital-administered therapies for acute and chronic care.
Government and public health programs purchase vaccines for population immunization.
Dispense prescribed medicines to patients and support recurring prescription volumes.
Influence which products are accessible and at what price through coverage decisions.
Recommend therapies and help drive prescribing uptake for branded medicines.
Strategy
Sanofi’s strategy centers on R&D-led innovation in immunology, vaccines, and other specialty therapeutic areas, supported by a broad global commercialization platform. The company also emphasizes pipeline development, disciplined capital allocation, and use of scientific and digital capabilities to expand future product opportunities and sustain its franchise. Portfolio actions and financing flexibility support the mix of mature medicines, new launches, and long-dated research programs.
New therapies and label expansions are central to long-term growth in biopharma.
Broad market access across countries converts approvals into revenue.
Asset sales, acquisitions, and financing decisions shape therapeutic mix and flexibility.
Discovery speed and development efficiency can improve competitiveness in pharma.
Geography
Sanofi operates globally, with its commercial footprint spanning Europe, the United States, and other international markets. The company’s reports indicate employee participation across 52 countries, underscoring a broad operating base, while its medicines and vaccines are sold through country-specific regulatory and reimbursement systems. Geography matters because pricing, access, and demand vary widely by market, especially between large developed healthcare systems and emerging markets.
Risks
Sanofi faces typical biopharma risks tied to clinical success, regulatory approval, intellectual property protection, and reimbursement pressure. Its reported estimates also highlight exposure to rebates, chargebacks, litigation, tax risks, and valuation judgments on goodwill and acquired intangibles, which can materially affect reported results. Global operations add foreign exchange, country-specific access, and geopolitical exposure across its commercial footprint.
- Patent and generic competitionImpact: HighLikelihood: High
Loss of exclusivity can reduce sales of established medicines.
Exposure: Mature originator products
- Clinical development failureImpact: HighLikelihood: Medium
Pharma revenue depends on successful trials, approvals, and launch execution.
Exposure: Pipeline programs in specialty care and vaccines
- Rebates and chargebacksImpact: MediumLikelihood: High
Reported sales depend on estimates for returns, rebates, and price reductions.
Exposure: U.S. and public payer channels
- Foreign exchange volatilityImpact: MediumLikelihood: High
A global revenue base creates translation and transaction exposure.
Exposure - Litigation and tax provisionsImpact: MediumLikelihood: Medium
Management must estimate legal and tax exposures that can move earnings.
Exposure: Corporate and product-related disputes
Accounting
Judgemental itemsSales are recorded net of rebates, chargebacks, incentives, and price reductions.
Impact: Affects reported net sales and gross-to-net trends
Acquired assets and goodwill depend on future cash flow assumptions.
Impact: Can cause non-cash write-downs if performance weakens
The company estimates liabilities for legal disputes and tax exposures.
Impact: Can create earnings volatility and balance-sheet changes
Global operations expose results to currency movements.
Impact: Affects reported sales, profit, and comparability
Management states activities are not subject to significant seasonal fluctuations.
Impact: Quarterly comparability is less affected by seasonality than in some industries
Similar listed companies
Publicly listed companies with a comparable business focus.
GSK plc
GSK · Pharmaceutical Preparations
GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Pfizer, Inc
PFE · Pharmaceutical Preparations
Novartis AG
NVS · Pharmaceutical Preparations
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas.
Takeda Pharmaceutical Company Limited
TAK · Pharmaceutical Preparations
Takeda Pharmaceutical is a Japan-headquartered biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines.
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
Last updated: 28/09/2026